A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
← catalyst calendarNCT07019922 · readout ≤ 133 d
Sponsored by Praxis Precision Medicines (industry) · PRAX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40estimated
Sites
10
Countries
Brazil, Germany, Italy +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-13 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epileptic Encephalopathy
- SCN2A Encephalopathy
Interventions
- Drug: 1mg elsunersen
- Drug: 0.5mg elsunersen
Primary outcome
what the primary-completion date above is the date OFTo assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEE
measured 24 weeks
Permalink · PRAX's whole pipeline · Catalyst calendar · Every registered study · What changed